Current Evidence of a Deintensification Strategy for Patients with HPV-Related Oropharyngeal Cancer.

ABSTRACT: Human papillomavirus (HPV)-related oropharyngeal cancer differs from HPV-negative oropharyngeal cancer in terms of etiology, epidemiology, and prognosis. Younger and lower comorbidity patient demographics and favorable prognosis allow HPV-related oropharyngeal cancer patients to anticipate longer life expectancy. Reducing long-term toxicities has become an increasingly important issue. Treatment deintensification to reduce toxicities has been investigated in terms of many aspects, and the reduction of radiotherapy (RT) dose in definitive treatment, replacement of platinum-based chemotherapy with cetuximab, response-tailored dose prescription after induction chemotherapy, and reduction of adjuvant RT dose after transoral surgery have been evaluated. We performed a literature review of prosp

SUBMITTER: Sung SY 

PROVIDER: S-EPMC9406155 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature